These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29117311)

  • 1. Ketamine Minus the Trip: New Hope for Treatment-Resistant Depression.
    Abbasi J
    JAMA; 2017 Nov; 318(20):1964-1966. PubMed ID: 29117311
    [No Abstract]   [Full Text] [Related]  

  • 2. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2018 Oct; 56(10):11-14. PubMed ID: 30278095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 5. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
    Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
    Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

  • 8. New use for an old drug: oral ketamine for treatment-resistant depression.
    Swiatek KM; Jordan K; Coffman J
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27489070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of ketamine.
    Stahl SM
    CNS Spectr; 2013 Aug; 18(4):171-4. PubMed ID: 23866089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esketamine nasal spray (Spravato) for treatment-resistant depression.
    Med Lett Drugs Ther; 2019 Apr; 61(1569):54-57. PubMed ID: 31169797
    [No Abstract]   [Full Text] [Related]  

  • 13. Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
    López-Díaz Á; Murillo-Izquierdo M; Moreno-Mellado E
    Br J Psychiatry; 2019 Aug; 215(2):447-448. PubMed ID: 31030677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Rapid-Acting Antidepressant.
    Krystal JH; Charney DS; Duman RS
    Cell; 2020 Apr; 181(1):7. PubMed ID: 32243798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.
    Correia-Melo FS; Silva SS; Araújo-de-Freitas L; Quarantini LC
    Braz J Psychiatry; 2017; 39(2):188-189. PubMed ID: 28591272
    [No Abstract]   [Full Text] [Related]  

  • 16. [Off-label ketamine treatment for treatment-resistant depression: win-win?].
    Smith-Apeldoorn SY; Veraart JKE; Schoevers RA
    Tijdschr Psychiatr; 2019; 61(8):516-518. PubMed ID: 31512733
    [No Abstract]   [Full Text] [Related]  

  • 17. Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish.
    Opler LA; Opler MG; Arnsten AF
    CNS Spectr; 2016 Feb; 21(1):12-22. PubMed ID: 25619798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of non-suppression of cortisol levels in a patient with refractory depression receiving ketamine.
    Ostroff R; Kothari JS
    Am J Psychiatry; 2015 Jan; 172(1):95-6. PubMed ID: 25553498
    [No Abstract]   [Full Text] [Related]  

  • 19. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
    Singh I; Morgan C; Curran V; Nutt D; Schlag A; McShane R
    Lancet Psychiatry; 2017 May; 4(5):419-426. PubMed ID: 28395988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.
    Murrough JW; Collins KA; Fields J; DeWilde KE; Phillips ML; Mathew SJ; Wong E; Tang CY; Charney DS; Iosifescu DV
    Transl Psychiatry; 2015 Feb; 5(2):e509. PubMed ID: 25689570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.